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Abstract
Background: Pyomyositis is a rare, subacute, deep pyogenic infection of the muscle tissue. This disease has been
previously described in patients that were immunocompromised due to a hematological malignancy.
Case Presentation: A 68-year-old man with a history of chronic myeloid leukemia was treated with imatinib. He
was diagnosed with ascending colon cancer and underwent curative surgery. His postoperative course was
uneventful, and he was healthy at 6 months after surgery, allowing for reinitiation of imatinib therapy. After the
reinitiation of therapy, a computed tomography (CT) scan revealed a mass shadow in the right iliopsoas muscle.
This lesion was clinically diagnosed as recurrent colon cancer with an abscess, which was resected surgically. A
pathological examination uncovered both edema and inflammation. Two months after the second surgery, imatinib
therapy was reinitiated; however, he again developed painful swelling and erythema in his right thigh. A CT scan
revealed a similar shadow as described previously. He was then diagnosed with pyomyositis; he underwent
incisional drainage and was administered linezolid. Following the treatment for pyomyositis, there was no cancer
recurrence or evidence of any recurrent pyomyositis.
Conclusions: Findings from this case suggest that both undergoing surgery and receiving imatinib therapy may
modulate an individual’s immune response, whereby the surgical site becomes more prone to infection and may
predispose an individual to pyomyositis. The case report is followed by a discussion of the literature regarding this
disease, including potential risk factors and the underlying pathogenesis.
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Background
Pyomyositis is a rare, subacute, deep pyogenic infection
of the muscle tissue [1]. The disease occurs most com-
monly in immunocompromised patients, such as those
with a hematological malignancy [2]. Without early treat-
ment, pyomyositis can cause significant morbidity and mor-
tality. However, many surgeons are unaware of this disease.
The exact cause of primary pyomyositis remains un-
clear; however, it is considered the result of hematogenous
spread of infection from an occult source. Secondary
pyomyositis is usually a consequence of a direct extension
from an infectious process. The pathogenesis of the
disease is not well understood; however, trauma, malnutri-
tion, viral and parasitic infections, bacteremia, immuno-
deficiency, and chronic illness are risk factors. Moreover,
primary pyomyositis is rare, and the diagnosis of this
disease can be delayed if the affected muscle is deeply situ-
ated, as local signs may not be apparent in such cases.
In patients with a hematological malignancy, pyomyo-
sitis is most commonly seen at the initial presentation of
acute lymphoblastic leukemia or during the course of
treatment [2, 3]. Cases of pyomyositis have been re-
ported in patients with chronic myeloid leukemia (CML)
treated with imatinib [4]. Commonly, immunocom-
promised patients are at a higher risk of developing pyo-
myositis. Pyomyositis associated with a surgical site has
not been previously reported in postoperative patients.
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The present report describes a rare case of pyomyositis
at a surgical site in a patient with CML.
Case presentation
A 68-year-old man was diagnosed with CML in 2009.
His complete blood cell count at the initial diagnosis
was as follows: a white blood cell (WBC) count of
24,500 cells/μL, neutrophil bands of 64 %, hemoglobin
level of 10 g/dL, platelet count of 537,000 cells/μL, and a
lactate dehydrogenase (LDH) level of 346 IU/L. He has
been treated with 300 mg of imatinib once a day. After
6 months, a complete cytogenetic response was achieved
and the 300-mg imatinib therapy with was continued. In
April 2010, he was diagnosed with T2N0M0, stage I
ascending colon cancer, and underwent curative surgery
with regional lymph node dissection without adjuvant
chemotherapy. His postoperative course was uneventful,
and he was healthy at 6 months after surgery, allowing
for reinitiation of the imatinib therapy (300 mg/day). In
November 2010, a computed tomography (CT) scan re-
vealed a mass shadow in the right iliopsoas muscle that
was contiguous with the site of the ileocolostomy (Fig. 1).
His body temperature was 37.2 °C, and the results of his
routine laboratory examination were as follows: WBC
count of 9700 cells/μL, C-reactive protein (CRP) level of
16.7 mg/dL, and LDH and creatine kinase (CK) levels
within the normal range. A CT-guided biopsy and total
colonoscopy did not demonstrate the presence of malig-
nant cells, and no bacteria were isolated from the
drained fluid culture. After 6 months, a CT scan re-
vealed that the mass shadow had enlarged. This lesion
was clinically diagnosed as recurrent colon cancer with
an abscess, which was then resected surgically. A patho-
logical examination uncovered both edema and inflam-
mation of the fascia and muscular tissues with the
presence of lymphocytes, neutrophils, plasma cells, and
foreign-body giant cells. The pathological diagnosis was
granulation tissue with no malignancy (Fig. 2a, b). The
patient’s postoperative course was good, and he was
healthy without recurrence at 2 months after the second
surgery, allowing for reinitiation of imatinib therapy
(300 mg/day). However, he developed painful swelling
and erythema on the right thigh after reinitiating ther-
apy. His body temperature was 37.4 °C, and the results
of his routine laboratory examination were as follows:
WBC count of 7100 cells/μL, CRP level of 1.93 mg/dL,
and LDH and CK levels within normal range. A CT scan
revealed a mass shadow extending from the right
Fig. 1 A computed tomography scan reveals a retroperitoneal
abscess close to the ileocolostomy. The retroperitoneal abscess and
fistula extends from the psoas abscess to the femoral abscess
(encircled by the dotted line)
Fig. 2 a A pathological examination shows granulation tissue with no malignancy. b Epidermotropism by lymphocytes and widespread
monocellular vacuolization of the epidermis in the granulation tissue (hematoxylin and eosin stain, ×100 magnification)
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iliopsoas muscle to the right thigh muscle 2 months
after the surgery for retroperitoneal granulation and ab-
scess (Fig. 3a–c). A femoral muscle biopsy showed no
malignancy. No bacteria were isolated from the blood
and drained fluid cultures. Despite the administration of
several antibiotics, the patient improved after starting an
oral linezolid therapy and undergoing incisional femoral
muscle drainage. The routine laboratory examination re-
sults were within normal range with values as follows: a
WBC count of 4500 cells/μL, CRP level of 0.2 mg/dL, and
LDH and CK levels within normal range. After that, he no
longer received oral imatinib therapy. There was no cancer
recurrence or evidence of any recurrent pyomyositis 2 years
after his recovery from final pyomyositis occurrence.
Discussion
This report described a case of pyomyositis at the surgi-
cal site that occurred in the context of a recurrent iliop-
soas abscess in a patient with CML. Pyomyositis is a rare
and rapidly progressive complication of hematological
disorders and can be a focus of infection [3]. Hayashi
et al. described three cases of pyomyositis in patients
Fig. 3 a–c A computed tomography scan reveals a retroperitoneal abscess 2 months after the surgery for retroperitoneal granulation and
abscess. It also shows a fistula extending from the psoas abscess to the femoral abscess, as in Fig. 1 (encircled by the dotted line)
Table 1 Reported cases of pyomyositis in patients with chronic myeloid leukemia treated with imatinib
Case no. Authors Year Age
(years)















2005 70 Male Left thigh None Oxacillin Switch to hydroxyurea Incision and drainage Good
2 Chen
et al. [4]
2011 17 Male Bilateral thigh None No antibiotics Discontinuation None Good
3 Our case 2016 68 Male Right thigh None Linezolid Discontinuation Incision and drainage Good
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with hematological disorders, and they were all associ-
ated with methicillin-resistant Staphylococcus aureus
(MRSA). They also described S. aureus as the most com-
mon pathogen associated with pyomyositis. However, its
identification from blood or fluid culture can be difficult.
MRSA pathogens were isolated from blood culture in 5 to
38 % of cases [3]. In our case, we performed several blood
and drained fluid cultures. However, no bacteria were iso-
lated from either the drained fluid or blood cultures at any
time. From this point, MRSA was considered to be the
pathogen in our case, so we administered linezolid. In
the early stage of pyomyositis, treatment with antibi-
otics alone can be effective for local infection control.
However, if abscess formation has begun, the combin-
ation of surgical drainage and medical intervention is
the chosen treatment regimen and usually leads to a
complete recovery.
There might be other factors related to pyomyositis
aside from bacterial infection. Some cases of pyomyositis
and fasciitis without bacterial infection have been de-
scribed [4, 5]. However, a case of pyomyositis associated
with a surgical site has not been previously described
(Table 1). In the present case, CML was initially treated
with imatinib therapy, and the patient experienced infec-
tious episodes after the reinitiation of imatinib therapy
in both instances. Imatinib is a selective inhibitor of
ABL, c-kit, and platelet-derived growth factor (PDGF)
kinases. Imatinib can modulate immunological homoeo-
stasis in vivo, explaining its wide and increasing range of
known immune side effects [4]. Common adverse effects
of imatinib include edema, nausea, vomiting, diarrhea,
muscle cramps, and cutaneous reactions, which are
accompanied by emergence of a circulating T cell clone
and autoantibodies against the nucleus. Jardin et al. sug-
gested that imatinib should be included in the group of
pseudolymphoma-inducing drugs [5]. Edema and fluid
retention are characteristic side effects of imatinib that
possibly result from the alteration of interstitial fluid
pressure control via the PDGF receptor [6]. We revealed
that surgery induces the production of adhesion mole-
cules, cytokines, vascular endothelial growth factors,
immunosuppressive agents, and TGF-β [7]. From these
points of view, we hypothesize that inflammation was
first observed at the surgical site, and surgery-induced
factors, including inflammatory mediators or angiogenic
factors, became concentrated at the surgical site. In the
context of these surgical factors, pyomyositis might have
been induced by imatinib.
Conclusions
Our findings from this case suggest that both undergo-
ing surgery and receiving imatinib therapy may modu-
late an individual’s immune response, whereby the
surgical site becomes more prone to infection and may
predispose an individual to pyomyositis. It is necessary
for surgeons to recognize pyomyositis as a possible post-
operative complication at the surgical site in immuno-
compromised patients.
Consent
Written informed consent for publication of this case
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Abbreviations
CML: chronic myeloid leukemia; CT: computed tomography;
MRSA: methicillin-resistant Staphylococcus aureus; PDGF: platelet-derived
growth factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KT, HS, TS, HO, HM, EM, YE, TT, and MT were involved in the care of patient.
MI carried out the pathological studies and provided the histological figures.
All authors have read and approved the final manuscript.
Author details
1Department of Surgery, Shiga University of Medical Science, Seta
Tsukinowa-cho, Otsu, Shiga 520-2192, Japan. 2Department of Hematology,
Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga
520-2192, Japan. 3Department of Clinical Laboratory Medicine, Shiga
University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192,
Japan. 4Department of Clinical Nursing, Shiga University of Medical Science,
Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan.
Received: 13 January 2016 Accepted: 13 April 2016
References
1. Bickels J, Ben-Sira L, Kessler A, Wientroub S. Primary pyomyositis. J Bone
Joint Surg. 2002;84-A(12):2277–86.
2. Falagas ME, Rafailidis PI, Kapaskelis A, Peppas G. Pyomyositis associated with
hematological malignancy: case report and review of the literature. Int J
Infect Dis. 2008;12(2):120–5.
3. Hayashi T, Nozaki M, Nonaka Y, Ohashi K, Sakamaki H, Nomura T.
Pyomyositis as a focus of infection in hematological disorders: a report of 3
cases. Int J Hematol. 2003;77(2):171–4.
4. Chen MC, Yang SH, Yao TK, Chong PN, Chen SH. Bilateral hip pain caused
by adductor pyomyositis as the initial presentation of chronic myeloid
leukemia in a 17-year-old child. Pediatr Neonatol. 2011;52(2):353–7.
5. Jardin F, Courville P, Lenain P, Lenormand B, Pouplin S, Contentin N,
Lehembre S, Laquerriere A, Clément JF, Tilly H. Concomitant eosinophilia,
fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies
in chronic myeloid leukaemia: role of a T-cell clone induced by imatinib.
Lancet Oncol. 2005;6(9):728–9.
6. Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM, Talpaz M.
Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002;95(4):881–7.
7. Takebayashi K, Murata S, Yamamoto H, Ishida M, Yamaguchi T, Kojima M,
Shimizu T, Shiomi H, Sonoda H, Naka S, Mekata E, Okabe H, Tani T. Surgery-
induced peritoneal cancer cells in patients who have undergone curative
gastrectomy for gastric cancer. Ann Surg Oncol. 2014;21(6):1991–7.
Takebayashi et al. World Journal of Surgical Oncology  (2016) 14:116 Page 4 of 4
